Lymphoma - cutaneous T-cell lymphoma

The Pharmaceutical Benefits Scheme (PBS) subsidises brentuximab vedotin or vorinostat for patients with cutaneous T-cell lymphoma (CTCL).

Patient eligibility

The PBS subsidises treatment with brentuximab vedotin under the National Health Act 1953, section 100 for patients with CTCL.

The PBS subsidises treatment with vorinostat under the National Health Act 1953 section 85 for patients with CTCL.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing brentuximab vedotin or vorinostat.

Section 100 arrangements

Brentuximab vedotin

This item is only available for day admitted patients, non-admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

This item isn’t PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Applications

Initial treatment

Brentuximab

Apply for authority approval to prescribe PBS subsidised brentuximab vedotin to treat CTCL in writing and either:

All applications must include the completed:

Vorinostat

Apply for authority approval to prescribe PBS subsidised vorinostat to treat CTCL in writing and either:

All applications must include the completed:

Continuing treatment

To apply for continuing PBS subsidised brentuximab vedotin or vorinostat to treat CTCL, call the PBS Complex Drugs Programs enquiry line.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 April 2019

Was this page useful?
Why?
Why not?

Thank you for your feedback.